Answers are grounded in this paper and cite their sources.
Signal - induced proliferation-associated 1-like protein 2 (SIPA1L2) is a large neuronal Rap GTPase-activating protein implicated in dynein-dependent retrograde transport of BDNF-TrkB signaling endosomes and genetically linked to Parkinson's disease. It consists of a RapGAP domain, a PDZ domain, and a coiled-coil domain separated by intrinsically disordered regions. Its compact PDZ domain mediates protein-protein interaction by binding short PDZ-binding motifs (PBM) in target proteins. Here, the human SIPA1L2 PDZ domain (residues 943-1027) was crystallized and its structure determined by molecular replacement. The domain adopts the canonical PDZ fold of six beta-strands forming two antiparallel beta-sheets flanked by two alpha-helices. The beta 2 - beta 3 loop, located next to the PBM binding groove, is unusually short - eight residues, against a 14-residue human-PDZome consensus. A BLASTP- and AlphaFold3-based survey across Metazoa shows that, despite PDZ sequence identities falling to ~25 %, the fold and the short loop are structurally conserved (Calpha; RMSD 0.5 - 0.8 Angstrom), indicating that this is a genuine, evolutionarily constrained architectural feature of SIPA1L2-type PDZ domains. PBM binding was not observed in co-crystallization trials. Native holdup assays against a neuronal proteome identified no specific partners for the SIPA1L2 PDZ domain. The structure retains the canonical carboxylate-binding loop and a class-I-type histidine, so partner scarcity is not due to loss of the PBM binding apparatus. Impaired PBM binding seems to result from the combination of the unusually short beta 2 - beta 3 loop and an evolutionarily invariant His964 located at the beta 2 strand. The short loop might restrict the conformational dynamics of the beta 2 strand, thereby stabilizing His964 side-chain conformations that encroach on the PBM binding groove. The structure thus defines SIPA1L2 as a structurally canonical yet apparently orphan PDZ domain.
No takes yet. Share an insight, caveat, or question.
Klos et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: